Industry Veteran and Wound Care Commercial Expert Dean Tozer Appointed as Executive Vice President and Chief Commercial Officer
Jennifer Linsky Appointed as Senior Director of National Accounts
GAITHERSBURG, Md., March 31, 2014 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, announced today the appointment of Dean Tozer as its Executive Vice President and Chief Commercial Officer. Mr. Tozer will be in charge of all commercial activity for AutoloGel and will lead the effort to drive product adoption in the estimated $3.4 billion U.S. wound care market. The Company also announced the appointment of Jennifer Linsky as its Senior Director of National Accounts.
Martin Rosendale, Chief Executive Officer of Cytomedix, commented, "Dean is one of the top professionals nationwide in the wound care specialty and has demonstrated exceptional ability in product commercialization. His appointment is a critical step in our efforts to build out the sales and marketing infrastructure for AutoloGel. In addition to his commercial and business development skills, he also brings in-depth knowledge of the reimbursement landscape and process, which is important to our growth. We look forward to the strategic insights and contributions he will make."
Mr. Rosendale added, "I would also like to welcome Jennifer Linsky to the team. Jennifer is a highly accomplished sales and marketing professional who has a demonstrated track record in building market share for healthcare products. She has significant experience in the wound care market and deep relationships with the major wound care management companies in the US. Her leadership skills and experience in wound care will be integral to AutoloGel brand building efforts."
Dean Tozer has more than 25 years' experience in the global healthcare industry and has an established track record of successfully launching and marketing wound care products. From 2006 – 2011 he was Senior Vice President at Advanced BioHealing Inc. where he was responsible for the acquisition and reintroduction of Dermagraft® into the U.S. market. Subsequently, Mr. Tozer became Vice President of Corporate Development at Shire Regenerative Medicine following the acquisition of Advanced BioHealing, where he led the business development efforts for that division including the 2012 acquisition of Pervasis Therapeutics. Prior to working at Shire, he served as a commercialization consultant to a variety of clients through independent consultancy Tozer & Associates. He also has eight years of global healthcare experience with Searle Pharmaceuticals, a Monsanto company. Mr. Tozer was also a founding executive and officer of the Alliance for Regenerative Medicine, where he served as Treasurer. He earned a Bachelor of Commerce degree from St. Mary's University in Halifax, Canada and is a Certified Management Accountant.
Jennifer Linsky also joins Cytomedix from Shire Regenerative Medicine, where she was a National Accounts Manager and National Manager of Market and Business Development. At Shire, she launched a business development and comprehensive disease management program initiative that increased the diabetic wound market potential nationwide. Ms. Linsky also spent more than 7 years in positions of increasing responsibility at GlaxoSmithKline, culminating in her promotion to a four-year position as a District Sales Manager. Ms. Linsky earned a Bachelor of Science in Nutritional Science/Pre-Medicine and graduated cum laude from Auburn University.
About Cytomedix
Cytomedix, Inc. is an autologous regenerative therapies company commercializing innovative platelet technologies for orthopedics and wound care. The Company markets the AutoloGel™ System (AutoloGel.com), a device for the production of autologous platelet rich plasma ("PRP") gel for use on a variety of exuding wounds. For additional information please visit cytomedix.com.
Safe Harbor Statement – Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, risks and uncertainties related to the Company's ability to successfully execute its Angel and AutoloGel sales strategies, its expectations relating to the size of the US wound care market as well as its ability to establish and increase its sales in such market, to achieve AutoloGel expected reimbursement rates in 2013, and thereafter, the Company's ability to collect the data necessary for the grant of the unconditional coverage, the Company's ability to continue in its efforts to expand in the wound care market, its ability to successfully negotiate with physician offices as anticipated and to realize the anticipated sales growth from such treatments, the likelihood of a favorable CMS determination relating to the reimbursement rates for AutoloGel™, to meet its stroke trial enrollment rates, to successfully realize sales of the Angel Technology resulting in the royalty stream to the Company, the Company's ability to successfully integrate the Aldagen acquisition, the Company's ability to expand patient populations as contemplated, its ability to provide Medicare patients with access as expected, the Company's expectations of favorable future dialogue with potential strategic partners, and its ability to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company's sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2012, as amended to date, and other subsequent filings. These filings are available at www.sec.gov.